Relmada Therapeutics (RLMD) Price & Analysis

Compare

354 Followers

RLMD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.24 - $3.98

Previous CloseN/A

Volume447.03K

Average Volume (3M)232.88K

Market Cap

$19.88M

Enterprise Value-$18.85M

Total Cash (Recent Filing)$27.06M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.10

Next Earnings

Nov 06, 2025

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding33,191,624

10 Day Avg. Volume161,670

30 Day Avg. Volume232,882

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.95

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.24

Forecast

1Y Price Target

$1.00

Price Target Upside66.67% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.

Market PotentialThe in-licensing of NDV-01 for treating NMIBC represents a multi-billion opportunity for Relmada Therapeutics Inc.

Safety And AdministrationNDV-01's intravesical procedure is quick, requires no anesthesia, and does not need new or dedicated equipment.

Bears Say

Financial PositionThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.

Uncertainties In DevelopmentThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.

ValuationAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.

Relmada Therapeutics News

Relmada Therapeutics appoints Lotan to Chair of Clinical Advisory Board

Relmada Therapeutics (RLMD) announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada’s...

24d ago

RLMD

Relmada Therapeutics Reports Promising Trial Results

Relmada Therapeutics Inc ( ($RLMD) ) has released its Q2 earnings. Here is a breakdown of the information...

10h ago

RLMD

Relmada Therapeutics Reports Promising Phase 2 Study Results

An announcement from Relmada Therapeutics ( ($RLMD) ) is now available. Relmada Therapeutics reported its second-quarter 2025 financial...

18h ago

RLMD

Relmada Therapeutics Granted Nasdaq Listing Extension

Relmada Therapeutics ( ($RLMD) ) has provided an announcement. On January 21, 2025, Relmada Therapeutics was notified by...

16d ago

RLMD

Relmada Therapeutics Ends Esmethadone License Agreement

An announcement from Relmada Therapeutics ( ($RLMD) ) is now available. Relmada Therapeutics announced the termination of its...

29d ago

RLMD

Relmada Therapeutics Appoints New Chief Medical Officer

Relmada Therapeutics ( ($RLMD) ) has issued an update. On June 17, 2025, Relmada Therapeutics announced the appointment...

2M ago

RLMD

Relmada Therapeutics appoints Raj Pruthi as CMO, Urology

Relmada Therapeutics (RLMD) announced the appointment of Raj S. Pruthi, MD as Chief Medical Officer-Urology. Dr. Pruthi’s expertise...

2M ago

RLMD

Relmada Therapeutics Holds Annual Stockholders Meeting

Relmada Therapeutics ( ($RLMD) ) just unveiled an update. On May 23, 2025, Relmada Therapeutics held its Annual...

2M ago

RLMD

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2M ago

TIL

IMNN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

CVM

TIL

Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns

Relmada Therapeutics Inc (($RLMD)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

RLMD

VA secretary wants to find answers on psychedelics therapies, Politico says

Veterans Affairs Secretary Doug Collins wants to find out whether psychedelic drugs can successfully treat veterans with PTSD...

3M ago

ATAI

CYBN

Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3M ago

TMO

ATAI

Relmada Therapeutics Reports Q1 2025 Financial Results

Relmada Therapeutics Inc ( ($RLMD) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

RLMD

RLMD FAQ

What was Relmada Therapeutics Inc’s price range in the past 12 months?

Relmada Therapeutics Inc lowest stock price was $0.24 and its highest was $3.98 in the past 12 months.

What is Relmada Therapeutics Inc’s market cap?

Relmada Therapeutics Inc’s market cap is $19.88M.

When is Relmada Therapeutics Inc’s upcoming earnings report date?

Relmada Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Relmada Therapeutics Inc’s earnings last quarter?

Relmada Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.16.

Is Relmada Therapeutics Inc overvalued?

According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Relmada Therapeutics Inc pay dividends?

Relmada Therapeutics Inc does not currently pay dividends.

What is Relmada Therapeutics Inc’s EPS estimate?

Relmada Therapeutics Inc’s EPS estimate is -0.45.

How many shares outstanding does Relmada Therapeutics Inc have?

Relmada Therapeutics Inc has 33,191,624 shares outstanding.

What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?

Relmada Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Relmada Therapeutics Inc?

Currently, no hedge funds are holding shares in RLMD

Company Description

Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics (RLMD) Earnings & Revenues

Historic Earnings Reports

RLMD Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong progress in product development with promising Phase 2 data for NDV-01 and sepranolone, as well as a disciplined financial approach. However, there are concerns about increased cash usage and a decreased cash position.View all RLMD earnings summaries

RLMD Stock 12 Month Forecast

Average Price Target

$1.00

▲(66.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.7323076923076923,0.7546153846153846,0.7769230769230769,0.7992307692307692,0.8215384615384616,0.8438461538461538,0.8661538461538462,0.8884615384615384,0.9107692307692308,0.933076923076923,0.9553846153846154,0.9776923076923076,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.7323076923076923,0.7546153846153846,0.7769230769230769,0.7992307692307692,0.8215384615384616,0.8438461538461538,0.8661538461538462,0.8884615384615384,0.9107692307692308,0.933076923076923,0.9553846153846154,0.9776923076923076,{"y":1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.7323076923076923,0.7546153846153846,0.7769230769230769,0.7992307692307692,0.8215384615384616,0.8438461538461538,0.8661538461538462,0.8884615384615384,0.9107692307692308,0.933076923076923,0.9553846153846154,0.9776923076923076,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.27,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >